Zahra, F. T., Turk, E., Ali, N. A., Haney, S., Drekolias, D., Vincelette, N., Song, J., Reynolds, S., Shallis, R., Xie, Z., Kuykendall, A., Sweet, K., Padron, E., Walker, A., Sallman, D., Komrokji, R., Lancet, J., Yun, S., Chan, O. (2025). Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML). Blood. https://doi.org/10.1182/blood-2025-291